Female doctor in consolidation with mother and child
icon-infectious-disease-testing
Syndromic testing

Tackle respiratory infections year-round

Meet the challenges that this respiratory season will bring

As COVID-19 public health measures are reduced, influenza-like illnesses (ILIs) and COVID-19 will converge this respiratory season. Similar symptomology between these pathogens and SARS-CoV-2, rising cases and the high risk of co-infections will likely present exceptional challenges to healthcare systems (1–3).

Diagnostic approaches using rapid molecular testing may help alleviate this burden (4,5). Highly multiplexed testing, commonly known as syndromic testing, can detect and differentiate >20 bacterial and viral pathogens in around one hour.

Latest insights

Syndromic testing, QIAstat-Dx Rise, instrument
Take your diagnostics to new heights

Meet the QIAstat-Dx Rise, the new higher-throughput member of the QIAstat-Dx family. The QIAstat-Dx Rise combines a quick and easy workflow with random access capabilities for increased testing capacity. This powerhouse instrument is uniquely built to fit the needs of high-demand institutions, helping you test up to 160 samples per day with eight Analytical Modules.

DISCOVER THE QIASTAT-DX RISE
Detection of emerging SARS-CoV-2 Delta, Mu and Omicron variants
The QIAstat-Dx Respiratory SARS-CoV-2 Panel remains capable of detecting SARS-CoV-2 infections in light of the emergence of new coronavirus variants, including Omicron (B.1.1.529).
LEARN MORE
Illustration of the Coronavirus, schematic drawing of the virus

Discover respiratory testing resources

Adopting a syndromic diagnostic approach to serve the community during COVID-19

When COVID-19 struck in Northwest Indiana, USA, CEO and president of Great Lakes Labs, Michelle Volk, knew that she wanted to help. She placed her trust in the QIAstat-Dx system to test for a wide range of pathogens, not just SARS-CoV-2, to help provide fast answers and peace of mind to her community.

 

read her story

Featured
–
explore syndromic respiratory testing

  • Confronting emerging COVID-19 variants
    Confronting emerging COVID-19 variants
    Over the course of the COVID-19 pandemic, data on novel SARS-CoV-2 variants with potentially increased transmissibility has continued to evolve Stay up to date on our continuous surveillance assessing the impact of mutations on assay sensitivity. (Updated September 2021)
    READ THE REPORT
  • COVID-19 and co-infection – what do we know?
    COVID-19 and co-infection – what do we know?
    Sometimes, testing for SARS-CoV-2 is not enough. A 30-study systematic review and meta-analysis published in the Journal of Infection suggests that some COVID-19 patients may be infected by more than one pathogen
    READ STUDY HIGHLIGHTS
  • Learn more about the QIAstat-Dx Respiratory SARS-CoV-2 Panel
    Multiple benefits to syndromic testing
    Traditional diagnostic methods, such as bacterial culture and microscopy, can take too long or are not sensitive enough. Learn how the benefits of syndromic testing go beyond improved patient care and extend throughout your hospital system.
    DISCOVER BENEFITS
Don’t just test for SARS-CoV-2 this season

In this webinar, QIAGEN Chief Medical Officer Dr. Davide Manissero discusses the role of syndromic testing during the ongoing COVID-19 pandemic. He also addresses the importance of time to diagnosis and potential for co-infections during respiratory season.

Watch now
Don’t just test for SARS-CoV-2 this season

Uniquely powerful
–
our solution for syndromic testing

  • Comprehensive pathogen identification
    Comprehensive pathogen identification
    The QIAstat-Dx Respiratory SARS-CoV-2 Panel offers:
    • Detection of 22 respiratory targets, including SARS-CoV-2
    • Comprehensive results in around 1 hour
  • Ct values and amplification curves
    Ct values and amplification curves

    The QIAstat-Dx System provides additional information that may help support diagnostic decision making:

    • Ct values
    • Amplification curves
  • Powerful connectivity features
    Powerful connectivity features

    Connection with the QIAsphere app provides*:

    • QIAstat-Dx Analyzer status updates – anytime, anywhere
    • Remote and proactive technical support
    • On-demand epidemiological reports
Learn more about the QIAstat-Dx Respiratory SARS-CoV-2 Panel
* Enterovirus and Rhinovirus are both detected, but not differentiated, with the QIAstat-Dx Respiratory SARS-CoV-2 Panel.
Learn more about the QIAstat-Dx Respiratory SARS-CoV-2 Panel

To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge detects and differentiates* 22 respiratory targets, including SARS-CoV-2 from nasopharyngeal swabs (NPS) eluted in universal transport media (UTM).

Download the flyer
icon-callout-help
Ready to learn how syndromic testing with QIAstat-Dx can benefit your institution?
Contact an expert

Additional resources

  • COVID-19 solutions and resources
    COVID-19 solutions and resources
    Learn more about how QIAGEN solutions can be used in the fight against COVID-19, or get in touch to let us know how we can support your lab.
    Find solutions
  • Verification guidelines for our respiratory assay
    Verification guidelines for our respiratory assay
    In this application note, read a sample protocol for verifying the performance of the QIAstat-Dx Respiratory SARS-CoV-2 Panel in your laboratory.
    Read the protocol
  • The benefits of syndromic testing extend beyond the pandemic
    The benefits of syndromic testing extend beyond the pandemic
    The team at Mako Medical in North Carolina, USA, recognizes senior living communities are especially vulnerable to disease outbreaks. Syndromic testing is used at this lab to ensure fast results.
    Read their story
  • QIAstat-Dx reporting at your fingertips
    QIAstat-Dx reporting at your fingertips
    Get complete visibility of QIAstat-Dx instrument status across your institute with push notifications in the QIAsphere app. The app works in harmony with your local network to help you maximize productivity – learn more in our connectivity guide.
    Get the guide
*Some features require a QIAstat-Dx Connectivity plan; flexible plans are available to meet your lab’s needs 

References
  1. Hodjat, P., Christensen, P.A., Subedi, S., Bernard, D.W., Olsen, R.J. and Long, S.W. (2021) The rapid reemergence of seasonal respiratory viruses in Houston, Texas, after relaxing COVID-19 restrictions. medRxiv. doi: https://doi.org/10.1101/2021.05.27.21257940
  2. Centers for Disease Control and Prevention Weekly U.S. Influenza Surveillance Report https://www.cdc.gov/flu/weekly/index.htm
  3. Centers for Disease Control and Prevention Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States https://emergency.cdc.gov/han/2021/han00443.asp
  4. European Centre for Disease Prevention and Control COVID-19 testing strategies and objectives https://www.ecdc.europa.eu/sites/default/files/documents/TestingStrategy_Objective-Sept-2020.pdf
  5. Centers for Disease Control and Prevention Testing Guidance for Clinicians When SARS-CoV-2 and Influenza Viruses are Co-circulating https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians-hospitaized.htm

The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory SARS-CoV-2 Panel are intended for in vitro diagnostic use.

The QIAstat-Dx Analyzer, QIAstat-Dx Rise and QIAstat-Dx Respiratory SARS-CoV-2 Panel are intended for in vitro diagnostic use.

Product availability may differ from country to country based on regulations and approvals. Contact your country representative for further details.

X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm